Figure 1

![Figure 1: Developmental and epileptic encephalopathies involve severe drug-resistant epilepsy with significant neurodevelopmental comorbidities. This figure summarizes the psychobehavioural and cognitive adverse events associated with anti-seizure medications used to treat these rare childhood-onset syndromes.](https://pdfs.citedhealth.com/figures/36194365/209.png)

> Source: Adam Strzelczyk et al. "Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for t." *CNS drugs*, 2022. PMID: [36194365](https://pubmed.ncbi.nlm.nih.gov/36194365/)

<figure>
  <img src="https://pdfs.citedhealth.com/figures/36194365/209.png" alt="Developmental and epileptic encephalopathies involve severe drug-resistant epilepsy with significant neurodevelopmental comorbidities. This figure summarizes the psychobehavioural and cognitive adverse events associated with anti-seizure medications used to treat these rare childhood-onset syndromes." />
  <figcaption>Figure 1. Developmental and epileptic encephalopathies involve severe drug-resistant epilepsy with significant neurodevelopmental comorbidities. This figure summarizes the psychobehavioural and cognitive adverse events associated with anti-seizure medications used to treat these rare childhood-onset syndromes.<br>  Source: Adam Strzelczyk et al. "Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for t." <em>CNS drugs</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36194365/">36194365</a></figcaption>
</figure>